Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study
Authors' conclusion
Findings from MIRAGE study demonstrated glycaemic and weight-loss benefits of semaglutide, with improvements in other cardiometabolic parameters. The study supports real-world OW subcutaneous semaglutide use in North Macedonia.
Study context
- Population
- GLP-1 RA naïve patients with T2D in routine clinical practice in North Macedonia; mean age 55.5 years, HbA1c 9.0 %, diabetes duration 7.8 years, body weight 105.2 kg
- Participants
- 314 patients
- Outcome
- Change in HbA1c from baseline
- Follow-up
- End of study (30 weeks)
Methodological detailsmulticentre, single-arm, real-world
- Multicentre
- Single-arm
- Real-world
Main finding
As reported in the abstract
Change in HbA1c from baseline to EOS · 30 weeks (EOS)
- Estimated mean change in HbA1c (% points)
- −2.2
- Statistical significance
- p < 0.0001
Observational data: associations, not effects.
Secondary outcomes
Change in body weight · end of study (EOS)
- Estimated mean change in body weight (kg)
- −9.0
- Statistical significance
- P < 0.0001
Change in fasting plasma glucose (FPG) · EOS
- Estimated mean change in FPG (mmol/L)
- −4.1
- Statistical significance
- P < 0.0001
HbA1c < 7 % achieved · EOS
- Patients achieving HbA1c < 7 %
- 62.1 %
≥ 1 % HbA1c reduction · EOS
- Patients with ≥ 1 % HbA1c reduction
- 79.3 %
Weight reduction ≥ 3 % and ≥ 5 % · EOS
%
- Weight reduction ≥ 3 %
- 88.3
- Weight reduction ≥ 5 %
- 73.3
Safety
- No new safety concern emerged
Original publication
Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study. Diabetes Res Clin Pract. Published 14 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →